Phase II trial of concurrent chemoradiotherapy with S‑1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma

Wen,Linchun; You,Chuanwen; Lu,Xiyan; Zhang,Longzhen

doi:10.3892/mco.2015.529

Phase II trial of concurrent chemoradiotherapy with S‑1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma

Authors:
- Linchun Wen
- Chuanwen You
- Xiyan Lu
- Longzhen Zhang
View Affiliations

Affiliations: Department of Oncology, Suqian People's Hospital of Nanjing, Gulou Hospital Group, Suqian, Jiangsu, P.R. China, Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China
Published online on: March 9, 2015 https://doi.org/10.3892/mco.2015.529
Pages: 687-691

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This is a prospective randomized trial performed to compare the efficacy of concurrent chemoradiotherapy (CCRT) + S‑1 (oral fluoropyrimidine) with that of CCRT + cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 105 eligible patients were randomly assigned to receive CCRT with S‑1 (S‑1 arm, n=50) or cisplatin weekly (control arm, n=55). Patients in the S‑1 arm received CCRT plus S‑1 (40‑60 mg, twice daily for 4 consecutive weeks. Patients in the control arm received standard cCRT with weekly cisplatin. All the patients were included in an intention‑to‑treat survival analysis. Our results demonstrated that the S‑1 and control arms did not differ significantly in terms of complete response, partial response, progression‑free survival or overall survival (all P‑values >0.05). However, the two arms varied significantly regarding certain grade 3‑4 toxicities, including leukopenia, 5.5 vs. 22.0% (P=0.013); mucositis, 20.0 vs. 46.0% (P=0.004); dermatitis, 15.5 vs. 32.7% (P=0.011); and nausea, 9.1 vs. 41.6% (P<0.001) for the S‑1 and control arms, respectively. In conclusion, CCRT with S‑1 was found to be similar in efficacy but superior in terms of toxicity compared to the standard CCRT with weekly cisplatin.

View Figures

View References

1	Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, Tan TD, Tsou MH and Huang AT: Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 41:755–762. 1998. View Article : Google Scholar : PubMed/NCBI
2	Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ and Fu KK: Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 48:711–722. 2000. View Article : Google Scholar : PubMed/NCBI
3	Cheng SH, Yen KL, Jian JJ, Tsai SY, Chu NM, Leu SY, Chan KY, Tan TD, Cheng JC, Hsieh CY and Huang AT: Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiat Oncol Biol Phys. 50:717–726. 2001. View Article : Google Scholar : PubMed/NCBI
4	Fareed MM, AlAmro AS, Bayoumi Y, Tunio MA, Ismail AS, Akasha R, Mubasher M and Al Asiri M: Intensity-modulated radiotherapy with simultaneous modulated accelerated boost technique and chemotherapy in patients with nasopharyngeal carcinoma. BMC Cancer. 13:3182013. View Article : Google Scholar : PubMed/NCBI
5	Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM and Zee B: Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 22:3053–3060. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zheng J, Wang G, Yang GY and Wang D, Luo X, Chen C, Zhang Z, Li Q, Xu W, Li Z and Wang D: Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol. 40:425–431. 2010. View Article : Google Scholar : PubMed/NCBI
7	Du C, Ying H, Zhou J, Hu C and Zhang Y: Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Int J Clin Oncol. 18:464–471. 2013. View Article : Google Scholar : PubMed/NCBI
8	Niu X, Hu C and Kong L: Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 139:1063–1071. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhong YH, Dai J, Wang XY, Xie CH, Chen G, Zeng L and Zhou YF: Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 71:1577–1583. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS and Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 21:631–637. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX and Mo HY: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 19:1350–1357. 2001.PubMed/NCBI
12	Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
13	Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN and Lui LT: Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 19:4305–4313. 2001.PubMed/NCBI
14	Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P and Johnson PJ: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 20:2038–2044. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ and Jang KM: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol. 20:892–896. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bae WK, Hwang JE, Shim HJ, Cho SH, Lee KH, Han HS, Song EK, Yun HJ, Cho IS, Lee JK, Lim SC, Chung WK and Chung IJ: Multicenter phase II study of weekly docetaxel, cisplatin and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. BMC Cancer. 13:1022013. View Article : Google Scholar : PubMed/NCBI
17	Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T and Okusaka T: A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 85:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
18	Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Choen JH, Jeung HC, Rha SY, Roh JK, Chung HC and Ahn JB: Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Radiother Oncol. 95:303–307. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC and Chan AT: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 27:242–249. 2009. View Article : Google Scholar : PubMed/NCBI
20	Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ and Hong WK: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer. 79:1279–1286. 1997. View Article : Google Scholar : PubMed/NCBI
21	Airoldi M, Gabriele P, Gabriele AM, Garzaro M, Raimondo L, Pedani F, Beatrice F, Pecorari G and Giordano C: Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin+taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 67:1027–1034. 2011. View Article : Google Scholar : PubMed/NCBI